CEU34 - Debate: Radioactive Iodine vs No Radioactive Iodine

Saturday, October 25, 2025

2:00 PM - 2:45 PM EDT

Speaker(s)

Whitney Goldner, MD (she/her/hers)

Professor and Division Head of Endocrinology, Metabolism, and Diabetes
University of Colorado Anschutz Medical Campus, United States
Michael Tuttle, MD (he/him/his)

Chief, Endocriology Service
Memorial Sloan Kettering Cancer Center
New York, New York, United States

Moderator(s)

Sara Ahmadi, MD

Brigham and Women's Hospital

Disclosure(s):

Whitney S. Goldner, MD: Siemens: Clinical Trial Investigator (Terminated, June 30, 2024)

Michael Tuttle, MD: No financial relationships to disclose

Learning Objectives:

Discuss RAI vs. no RAI in patients with thyroid cancer and ATA intermediate risk of recurrence.
Discuss different approaches to managing patients with intermediate risk of recurrence and available data to support these approaches.

This session will review the controversy in managing patients with thyroid cancer and intermediate risk of recurrence. This is a case-based session. The moderator will present cases to the panelists and ask for their opinion on the patient’s management.